COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Golden Leaf Closes C$7.9 million Private Placement of Unsecured Convertible Subordinated Debenture Units16/11/2018
-   
  Letter to Shareholders to accompany recent proxy filing16/11/2018
-   
  Flexion Therapeutics Named Top Place to Work for Second Consecutive Year by The Boston Globe16/11/2018
-   
  New Findings Presented at the VEITHsymposium Reiterate Consistent, Durable Outcomes in Complex Aortic Disease with Heli-FX(TM) Endoanchor(TM) System16/11/2018
-   
  ATW Tech Provides Additional Information Regarding Signature of a Letter of Intent for Major Acquisition of Greywolf Entertainment Group16/11/2018
-   
  ATW Tech fournit de l’information additionnelle sur la signature de la lettre d’intention pour l’acquisition majeure du Groupe Greywolf Entertainement16/11/2018
-   
  Lifestyle Brand Weekend Unlimited Expanding Into Key US, Foreign Markets -- CFN Media16/11/2018
-   
  Menlo Therapeutics to Participate in the 30th Annual Piper Jaffray Healthcare Conference16/11/2018
-   
  Aurora Spine Announces Exclusive Patent License Agreement for MIS SI Joint Product16/11/2018
-   
  Dragon Jade Announces Filing of Registration Statement for Proposed Registered Offering16/11/2018
-   
  Novartis receives positive CHMP opinion to expand Kisqali® combination therapy to all women with HR+/HER2- locally advanced or metastatic breast cancer16/11/2018
-   
  Progressive Care Inc. Announces Record-Breaking October 201816/11/2018
-   
  Neon Therapeutics Named a Top Place to Work in Massachusetts by The Boston Globe16/11/2018
-   
  Imprimis Pharmaceuticals Ranked 88th Fastest Growing Company in North America on Deloitte’s 2018 Technology Fast 500™16/11/2018
-   
  Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)16/11/2018
-   
  Sanofi: European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness16/11/2018
-   
  Sanofi : L'Agence européenne des médicaments recommande l'approbation du fexinidazole, le premier traitement entièrement par voie orale de la maladie du sommeil16/11/2018
-   
  BeiGene Announces Preliminary Clinical Data on PARP Inhibitor Pamiparib Presented at Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology16/11/2018
-   
  BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology16/11/2018
Pages